• PDF / 170,687 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 24 Downloads / 139 Views

DOWNLOAD

REPORT

---

1 S

Interstitial lung disease: 7 case reports In a retrospective, single-centre study of 37 patients with advanced pancreatic ductal adenocarcinoma (PDAC) treated at a hospital in Japan between December 2014 and June 2019, 7 patients including 5 men and 2 women aged 64–78 years were described, who developed interstitial lung disease (ILD) during chemotherapy with gemcitabine and paclitaxel for advanced PDAC [times to reactions onsets not stated]. All patients had been pathologically diagnosed with advanced PDAC. All patients started receiving palliative chemotherapy with IV paclitaxel [nab-paclitaxel] 125 mg/m2, followed by a 30-min IV infusion of gemcitabine 1000 mg/m2 on days 1, 8 and 15 in a 4-week cycles. All patient routinely underwent radiographic findings. One patient, who had previously received first-line chemotherapy with fluorouracil, folinic-acid [leucovorin], irinotecan and oxaliplatin [FOLFIRINOX], received gemcitabine and paclitaxel as second-line chemotherapy, and other 6 patients received gemcitabine and paclitaxel as first-line chemotherapy. However, they developed ILD after 2–7 cycles of gemcitabine and paclitaxel therapy. Four patients had clinical symptoms of fatigue, cough or fever, and the other 3 patients were diagnosed with ILD incidentally during routine CT scan (imaging work-up). One patient also developed hypoxia (oxygen saturation